Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc Issues FY 2013 Earnings Guidance Above Analysts' Estimates


Thursday, 28 Feb 2013 08:31am EST 

Isis Pharmaceuticals Inc announced that for fiscal 2013, it expects pro forma net operating loss (NOL) in the mid $60 million range. According to I/B/E/S estimates, analysts were expecting the Company to report EBIT of (86.94) million for fiscal 2013. 

Company Quote

30.62
-0.77 -2.45%
4:00pm EDT